Semi-Annual Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7269903

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,681,015,000 JPY
-1,935,578,000 JPY
Depreciation
815,000 JPY
2,286,000 JPY
Impairment losses
17,104,000 JPY
21,898,000 JPY
Interest and dividend income
-2,150,000 JPY
-1,478,000 JPY
Interest expenses
4,597,000 JPY
3,602,000 JPY
Foreign exchange losses (gains)
-28,429,000 JPY
-24,090,000 JPY
Decrease (increase) in inventories
764,000 JPY
18,907,000 JPY
Other, net
11,504,000 JPY
20,812,000 JPY
Subtotal
-2,014,856,000 JPY
-1,359,074,000 JPY
Interest and dividends received
2,049,000 JPY
616,000 JPY
Interest paid
-4,337,000 JPY
-3,836,000 JPY
Net cash provided by (used in) operating activities
-2,020,088,000 JPY
-1,336,922,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-3,519,000 JPY
-5,686,000 JPY
Proceeds from sale of property, plant and equipment
JPY
136,000 JPY
Net cash provided by (used in) investing activities
-4,705,000 JPY
-5,392,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Repayments of long-term borrowings
-94,444,000 JPY
-194,444,000 JPY
Proceeds from issuance of shares
2,890,817,000 JPY
1,223,450,000 JPY
Net cash provided by (used in) financing activities
2,879,444,000 JPY
1,142,542,000 JPY
Effect of exchange rate change on cash and cash equivalents
23,504,000 JPY
21,334,000 JPY
Net increase (decrease) in cash and cash equivalents
878,155,000 JPY
-178,437,000 JPY
Cash and cash equivalents
2,165,918,000 JPY
1,287,763,000 JPY
1,466,201,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.